Eupraxia Pharmaceuticals Inc.

EPRX Nasdaq SEC CIK 1581178
Follow Eupraxia Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 USD · US GAAP
Revenue, last year $0
Net income −$38.6M −51.3% vs prior year
EPS, diluted −$1.03 −35.5% vs prior year
Operating cash flow −$28.6M +4.8% vs prior year
Revenue by fiscal year
$0
$0
$0
FY23 FY24 FY25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−$40M−$30M−$20M−$10M$0FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0−$38.6M
FY24$0−$25.5M
FY23$0−$28.2M
FY22-−$18.5M
FY21--